相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Economic burden of Parkinson's disease in Singapore
Y. J. Zhao et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Costs of illness and care in Parkinson's Disease: An evaluation in six countries
Sonja von Campenhausen et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2011)
Projected Numbers of People With Movement Disorders in the Years 2030 and 2050
Jan-Philipp Bach et al.
MOVEMENT DISORDERS (2011)
Modelling the Cost Effectiveness of Treatments for Parkinson's Disease A Methodological Review
Judith Dams et al.
PHARMACOECONOMICS (2011)
A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK
Julia Lowin et al.
JOURNAL OF MEDICAL ECONOMICS (2011)
The Use of Decision-Analytic Models in Parkinson's Disease
James Shearer et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2011)
Parkinson's Disease: Cost-of-Illness in an Outpatient Cohort
J. P. Reese et al.
GESUNDHEITSWESEN (2011)
Treatment of Advanced Parkinson's Disease in the United States A Cost-Utility Model
Huybert Groenendaal et al.
CLINICAL DRUG INVESTIGATION (2010)
Efficacy of community-based physiotherapy networks for patients with Parkinson's disease: a cluster-randomised trial
Morten Munneke et al.
LANCET NEUROLOGY (2010)
Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study
Yaroslav Winter et al.
NEURODEGENERATIVE DISEASES (2010)
Costs of Parkinson's disease in Eastern Europe: A Czech cohort study
Yaroslav Winter et al.
PARKINSONISM & RELATED DISORDERS (2010)
Trials of neuroprotective therapies for Parkinson's disease: Problems and limitations
Raul de la Fuente-Fernandez et al.
PARKINSONISM & RELATED DISORDERS (2010)
Discrete Event Simulation: The Preferred Technique for Health Economic Evaluations?
Jaime J. Caro et al.
VALUE IN HEALTH (2010)
Reducing Uncertainty in Value-Based Pricing Using Evidence Development Agreements The Case of Continuous Intraduodenal Infusion of Levodopa/Carbidopa (Duodopa®) in Sweden
Michael Willis et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2010)
Progression of Parkinson's disease in the clinical phase: potential markers
Walter Maetzler et al.
LANCET NEUROLOGY (2009)
Direct costs for Parkinson's treatment in private neurology practices in Berlin
R. Ehret et al.
NERVENARZT (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease
Carl E. Clarke et al.
PARKINSONISM & RELATED DISORDERS (2009)
Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease
Angelo Antonini et al.
PARKINSONISM & RELATED DISORDERS (2009)
Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease
Yaroslav Winter et al.
PHARMACOECONOMICS (2009)
Assessing health-related quality of life in patients with restless legs syndrome
Svenja Happe et al.
SLEEP MEDICINE (2009)
Cost of illness and health service patterns in Morbus Parkinson in Austria
Sonja von Campenhausen et al.
WIENER KLINISCHE WOCHENSCHRIFT (2009)
Short-Term Cost and Health Consequences of Duodenal Levodopa Infusion in Advanced Parkinson's Disease in Sweden An Exploratory Study
Ivar Kristiansen et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2009)
Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion
D. Isacson et al.
ACTA NEUROLOGICA SCANDINAVICA (2008)
Cost effectiveness of pharmacotherapies in early Parkinson's disease
Karla M. Eggert et al.
CNS DRUGS (2008)
Treatment of levodopa-induced motor complications
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2008)
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease
Francesc Valldeoriola et al.
MOVEMENT DISORDERS (2007)
The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation
Katia Noyes et al.
MEDICAL DECISION MAKING (2007)
Predicting the cost of Parkinson's disease
Paul McCrone et al.
MOVEMENT DISORDERS (2007)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Prospective study of the direct and indirect costs of idiopathic Parkinson's disease
I. Dengler et al.
NERVENARZT (2006)
Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China
Gang Wang et al.
MOVEMENT DISORDERS (2006)
Drug costs for patients with Parkinson's disease in two different European countries
C Vossius et al.
ACTA NEUROLOGICA SCANDINAVICA (2006)
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland
J Hudry et al.
ANNALS OF PHARMACOTHERAPY (2006)
Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease
V Fraix et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2006)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
A review of the health-related quality of life and economic impact of Parkinson's disease
Clare H. Dowding et al.
DRUGS & AGING (2006)
Economic evaluation of rivastigmine in patients with Parkinson's disease dementia
AR Willan et al.
PHARMACOECONOMICS (2006)
Burden of illness in Parkinson's disease
DM Huse et al.
MOVEMENT DISORDERS (2005)
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off
LJ Findley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Cost of Parkinson's disease in Europe
P Lindgren et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany
W Meissner et al.
JOURNAL OF NEUROLOGY (2005)
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
D Nyholm et al.
NEUROLOGY (2005)
Cost of illness and its predictors for Parkinson's disease in Germany
AE Spottke et al.
PHARMACOECONOMICS (2005)
Systematic assessment of decision models in Parkinson's disease
U Siebert et al.
VALUE IN HEALTH (2004)
Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs
PD Charles et al.
PARKINSONISM & RELATED DISORDERS (2004)
Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease
AL Green et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2004)
Surgery for Parkinson disease in the United States, 1996 to 2000: practice patterns, short-term outcomes, and hospital charges in a nationwide sample
EN Eskandar et al.
JOURNAL OF NEUROSURGERY (2003)
Direct economic impact of Parkinson's disease: A research survey in the United Kingdom
L Findley et al.
MOVEMENT DISORDERS (2003)
Estimating the costs of surgical innovations: The case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease
E McIntosh et al.
MOVEMENT DISORDERS (2003)
Longitudinal outcome of Parkinson's disease patients with psychosis
SA Factor et al.
NEUROLOGY (2003)
Clinical and economic analysis of spa therapy in Parkinson's disease
C Brefel-Courbon et al.
MOVEMENT DISORDERS (2003)
Economic burden and quality of life impairment increase with severity of PD
T Keranen et al.
PARKINSONISM & RELATED DISORDERS (2003)
Resource use and costs in a Swedish cohort of patients with Parkinson's disease
P Hagell et al.
MOVEMENT DISORDERS (2002)
Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus
EA Spottke et al.
JOURNAL OF NEUROLOGY (2002)
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States
CS Palmer et al.
PHARMACOECONOMICS (2002)
Deep brain stimulation in the treatment of Parkinson's disease - A cost-effectiveness analysis
KJ Tomaszewski et al.
NEUROLOGY (2001)
Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan
T Shimbo et al.
PHARMACOECONOMICS (2001)
Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study
D Aarsland et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2000)
分享论文
